(Ascites chylous)
2,174 results
  • Multi-cavity Primary Effusion Lymphoma in a Cirrhotic Patient: A Rare Cause of Chylous Effusion. [Case Reports]
    Cureus. 2026 May; 18(5):e109242.Chand T, Rab S, … Ravindran HC
  • Primary effusion lymphoma (PE) is a rare form of non-Hodgkin lymphoma characterized by malignant lymphatic effusion in the pleural cavity. Non-traumatic chylothorax is usually caused by lymphomas with a discrete lymph node mass. Our report presents a case where chylothorax and chylous ascites were clinical presentation of primary effusion lymphoma (PEL), a rare entity that does not show the typic…
  • Innovations in Reconstructive Microsurgery: A Series of Challenging Cases and Novel Techniques. [Review]
    Semin Plast Surg. 2026 May; 40(2):155-162.Chen HC, Tang YB, Lin CHSP
  • This presentation highlights a series of challenging reconstructive microsurgery cases encountered over the past 45 years. Selected cases from a collection of 500 unusual scenarios demonstrate innovative techniques developed to address complex reconstructive problems, aiming to stimulate discussion and further advancements in the field. These include refinements in microvascular anastomosis, nove…
  • Contemporary Perioperative Outcomes of Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer. [Journal Article]
    J Endourol. 2026 Jul; 40(7):766-772.Qian Z, Zhangxu K, … Clinton TNJE
  • CONCLUSIONS: R-RPLND demonstrates favorable perioperative outcomes at both institutional and national levels, with increasing utilization over the past decade. The minimally invasive approach may reduce the morbidity of open surgery and serve as an alternative to chemoradiation in early-stage testicular cancer in selected patients. Further studies are needed to evaluate long-term oncologic outcomes and cost-effectiveness.
  • Chylous Ascites: A Rare Initial Presentation of High-Grade Follicular Lymphoma. [Journal Article]
    Case Rep Oncol Med. 2026; 2026:5559043.Nada R, Gvajaia A, … Raji MCR
  • CONCLUSIONS: This case highlights chylous ascites as a rare but important presenting feature of lymphoma. Its recognition should prompt early histopathologic evaluation and multidisciplinary management. In selected postoperative or frail patients, rituximab monotherapy can serve as an effective bridge to full chemotherapy, facilitating recovery and improving outcomes. Early diagnosis and targeted treatment remain essential to prevent complications from lymphatic loss and to optimize prognosis in lymphoma-associated chylous ascites.